Analysis: Biotech's resistance to generics might be valid

03/3/2004 | Wall Street Journal, The

Biotech officials often point to the case of problems resulting from a generic version of Johnson & Johnson's Eprex drug as evidence problems can arise from allowing cheaper versions of biotech drugs. Unlike most drugs, these medicines use bioengineered cells, which can produce different results upon duplication. Generic drug makers say they recognize the problem and are looking for safe ways to copy biotech drugs and reduce the approval process. The FDA is also drafting scientific guidelines to address this issue.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID